Association between perioperative low-molecular-weight heparin vs unfractionated heparin and clinical outcomes in...

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Cancer patients undergoing surgery face elevated risks of venous thromboembolism (VTE).
• Perioperative thromboprophylaxis is crucial for mitigating VTE and associated complications in this high-risk population.
• Heparin anticoagulants, including low-molecular-weight heparin (LMWH) and unfractionated heparin, are commonly used for VTE prevention.

Purpose of the Study:

• To compare the efficacy and safety of LMWH versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer.
• To evaluate the association of these anticoagulants with mortality, pulmonary embolism, deep venous thrombosis, thrombocytopenia, and bleeding outcomes.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials and observational studies.
• Inclusion of studies comparing LMWH and unfractionated heparin in surgical cancer patients.
• Assessment of primary outcomes including mortality, VTE events, and bleeding complications.

Main Results:

• No significant difference was observed between LMWH and unfractionated heparin regarding mortality.
• Pulmonary embolism and deep venous thrombosis rates were comparable between the two heparin groups.
• Bleeding outcomes and the incidence of thrombocytopenia did not differ significantly between patients receiving LMWH or unfractionated heparin.

Conclusions:

• LMWH and unfractionated heparin demonstrate equivalent efficacy and safety profiles for perioperative thromboprophylaxis in cancer patients.
• The choice between LMWH and unfractionated heparin may be guided by factors such as cost, administration convenience, and specific patient characteristics.
• Both agents are effective in preventing VTE and associated complications without increasing bleeding risk in this population.